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 Response to non-noxious 
stimuli 
 Increase in responsiveness 
to suprathreshold 
stimulation 
 Expansion of pain area 
 Recruitment of nociceptive 
neurons from higher levels  
 Hyperalgesia 
 Allodynia  
Involvement of serotonin system 
Repetitive activation of nociceptive pathways 
Chronic paracetamol 
administration 
Acute paracetamol 
administration  
Paracetamol as the cause 
• Extracellular 5-HT levels 
increase. 
• Maximal number of 
cortical 5-HT2A receptors 
decrease. 
• Down-regulation of 
postsynaptics 5-HT2A 
receptors: ↓binding-sites. 
• Descending 
serotoninergic pathways 
inhibit nociceptive stimuli 
by: 
•Hyperpolarization of 
projection neurons 
or central terminalis 
of primary afferent 
fibers. 
•Excitation of 
inhibitory 
interneurons 
containing GABA 
and enkephalin. 
• Extracellular 5-HT levels 
decrease. 
• 5-HT2A receptors density 
increase. 
• Up-regulation of 5-HT2A 
receptors: ↑ binding 
sites. 
• 5-HT2A activation → ↑ 
COX-2 (nociceptive 
messenger). 
• Loss of analgesic 
efficacy, restoration of 
sensitivity, hyperalgesia, 
potentiation of 
nociceptive transmission.  
5-HT2A 
receptors 
density 
increase 
Paracetamol and Sensitisation 
Up-regulation 
of 5-HT2A 
receptors: ↑ 
binding sites 
5-HT levels 
decrease 
5-HT depletion   
↑ COX-2 in 
the parietal 
cortex 
↑ activation  5-
HT2A receptors 
Pain 
Central Sensitisation 
• Nociceptors become more sensible 
• Enlargement of the receptive fields 
• Activation of previously silent  
         nociceptors 
• Biological and functional changes  
         in the trigeminal nucleus 
• Changes in PAG 
Repetitive activation 
of C and 
unmyelinated fibers 
(≥0,5 Hz) 
Biochemical 
changes 
↑ 
glutamate 
and 
substance 
P 
↑ 
calcitonin 
gene-
related 
peptide 
Removal of 
voltage-
dependent 
blockade 
by Mg2+ 
Cascade 
mediated 
by 
neuronal 
receptors 
NMDA-like 
Aberrant 
and 
apoptosis 
of 
GABAergic 
neurons 
Distortion 
of pain 
Genetic 
changes 
MAPK 
Regulation 
of key 
gene 
products 
Fos 
activation 
in the 
cerebral 
cortex 
PAG 
changes 
Release of 
free 
oxygen 
radicals 
PAG 
tissue 
damage 
Increased 
iron 
deposition 
Irreversible 
oxidative 
changes in 
PAG 
NMDA 
receptors 
recruited 
Transient ↑ 
intracellular 
Ca2+ in 
postsynaptic 
neurons 
Calmodulin
dependent 
protein 
kinases 
activation  
Substantial 
changes in 
postsynaptic 
cells 
↑ 
membrane 
excitability 
Changes in 
genetic 
transcrip-
tion 
NO 
synthase 
activation 
↑ NO 
production 
and 
stimulation 
transmitter 
release 
LTP 
Synaptic 
potential 
long-
lasting 
changes 
Summation 
of changes 
over time 
Wind-up 
↑ dorsal 
horn 
respon-
siveness 
Direct effect of 
paracetamol on 
the capacity of 
the brain to 
inhibit pain 
5-HT 
involvement 
Mixture of 
Both causes 
"Off-cells" 
inhibition 
"Off-cells” 
from ventro-
medial 
medulla 
cannot 
inhibit 
nociception 
"On-cells" 
activation 
Nociception 
facilitation in 
trigeminal 
nucleus 
caudalis 
Nociception increase and Central Sensitisation 
• One of the principal mechanisms involved in MOH development lies in the integrity of serotonin system, either 
with serotonin or its 5-HT2A receptor. It is curious how an acute intake of paracetamol can lead to analgesia 
whereas a chronic intake leads to the opposite: pain.  
 
 
• Another of the main mechanisms are central sensitisation and cellular changes that suffer nociceptive neurons, 
either by repetitive activation of these pathways or the involvement of paracetamol in central sensitisation. 
 
Abbreviations used:  
• Central sensitisation (CS) 
• Central Nervous System (CNS) 
• Cyclooxygenase (COX) 
• Cytoplasmic (CY) 
• Long-term potentiation (LTP) 
 
 
 
• Medication-Overuse Headache 
(MOH) 
• Non-steroidal anti-inflammatory 
drugs (NSAID) 
• Over-the-counter (OTC) 
• Periaqueductal Grey Matter (PAG) 
• Serotonin (5-HT) 
 
• OTC NSAID. 
• Analgesic and antipyretic effects, not anti-inflammatory. 
• Central effect (ability to penetrate into the brain), inhibition of COX-3. 
• Mechanisms contributing to its antinociception effect: 
Legend: 
AA – Arachidonic acid 
AM404 - N-
arachidonoylaminophenol  
APAP – Paracetamol 
CB1R – Cannabinoid 1 receptor 
COX – Cyclooxygenase 
FAAH – Fatty acid amide hydrolase 
KOR – Kappa opioid receptor 
MOR – Mu opioid receptor 
NAPE – N-
acylphosphatidylethanolamine 
 
 
 
NAT – N-acyltransferase 
NO – Nitric Oxide 
PA – Palmitic Acid 
PAG – Periaqueductal Grey 
PC – Phospatidylcholine 
PE – Phospatidylethanolamine 
PEA – Palmitoylethanolamide 
PLD – Phospolipase D 
PPAR-α – Peroxisome proliferator-
activated receptor-α  
RVM – Rostral Ventral Medulla 
  
  
Objective: make a bibliography review in order to establish how 
paracetamol overuse can cause MOH and to investigate the 
pharmacological and physiopathological mechanisms involved in MOH 
development. 
Most commonly self-used NSAID to treat headache globally: Ibuprophen, 
Aspirin, Paracetamol (the most used in Europe). 
 
General unawareness of the risk of developing MOH.  
The term MOH first appeared in 2004. 
Headache ≥ 15 
days/month 
Regular taken 
analgesics ≥ 15 
days/month 
Regular 
overuse of 
analgesics for ≥ 
3 months 
Resolves after 2 
months of 
discontinuation 
of analgesics 
MOH 
• Paracetamol 
• Aspirin 
• Opioids 
• Ergotamine 
• Butalbital 
• Caffeine  combinations 
High risk of developing MOH 
• Triptans 
• Short-acting NSAIDs 
Medium risk of developing MOH 
• Long-acting NSAIDs 
• Dihydroergotamine 
• Tramadol 
• Neuroleptics 
Low risk of developing MOH 
Only individuals with a primary 
headache develop MOH. 
 
Epidemiology: 
• 1,5% global population 
(2,6% ♀, 0,19 ♂). 
• Spain: 1,41%  population 
(2,6♀ and 0,2%♂). 
Cellular adaptation in the brain 
Chronic exposure causes an impairment of the modulatory neurons in the 
CNS (abnormal membrane transduction). 
Glucose metabolism alteration 
Increased glucose metabolism in insula (pain experience). 
• In general, type headache diagnosis is difficult, especially with MOH, which is a recent-discovered pathology. That 
is the reason why physiopathological and pharmacological mechanisms involved in MOH are little known. 
However, this topic is under investigation and some important findings and interesting hypotheses have been 
discovered. 
 
 
• There are two principal aetiological groups of MOH that are interconnected; they imply reiterated use of 
paracetamol and repetitive activation of nociceptive pathways. This activation is basically due to treatment of the 
pain symptoms but not the real cause or origin of headache. 
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Paracetamol addiction (Hypoteses) 
• Compulsive reward-seeking. 
• Behaviioural sensitisation induced by drug administration in addiction. 
• Dopamine involvement: pain and reward. Central Sensitisation 
Methods: bibliographical search in PubMed and ScienceDirect, specially 
scientific papers and reviews. 
Figure 2. Possible paracetamol action mechanisms   
Figure 1. Paracetamol chemical structure 
Figure 3. MOH features   
Figure 4. Paracetamol effects in acute and chronic administration 
Figure 5. Mechanisms involving pain with paracetamol chronic administration 
Figure 6. Mechanisms involving CS due to a repetitive activation of nociceptive pathways  
Figure 7. Mechanisms involving CS due to chronic paracetamol administration 
